Assessment of therapeutic plasmapheresis in demyelinating neurologic disorders.
Considerable controversy exists with regard to therapeutic efficacy of plasmapheresis in the immune-mediated demyelinating disorders of the peripheral and central nervous system: acute inflammatory polyneuropathy (Guillain-Barré syndrome), chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis. In an effort to establish specific situations where plasmapheresis was of therapeutic value, we reviewed the experience at Southwestern Medical School, University of Texas Health Science Center at Dallas, and that published in the literature. In acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome), plasmapheresis may prevent progression of the illness, and it significantly increases the rate of recovery. For patients with chronic inflammatory polyneuropathy, plasmapheresis has produced clinical improvement in 50% of corticosteroid-refractory patients. The use of plasmapheresis in patients with acute or chronic progressive multiple sclerosis still remains controversial.
D000293:Adolescent; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D003711:Demyelinating Diseases / Q000175:diagnosis / Q000628:therapy*; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000628:therapy; D010523:Peripheral Nervous System Diseases / Q000628:therapy; D010956:Plasmapheresis; D011129:Polyradiculoneuropathy / Q000175:diagnosis / Q000628:therapy; D011446:Prospective Studies; D012008:Recurrence; D013997:Time Factors
D007166:Immunosuppressive Agents